TY - JOUR
T1 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Coronary Microvascular Dysfunction in Early Nonobstructive Coronary Artery Disease
AU - Akhiyat, Nadia
AU - Lasho, Terra
AU - Ganji, Morsaleh
AU - Toya, Takumi
AU - Shi, Chang Xin
AU - Chen, Xianfeng
AU - Braggio, Esteban
AU - Ahmad, Ali
AU - Corban, Michel T.
AU - Stewart, Keith
AU - Fernandez, Jenna
AU - Xie, Zhuoer
AU - Finke, Christy
AU - Lerman, Lilach O.
AU - Patnaik, Mrinal M.
AU - Lerman, Amir
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health (DK120292, DK122734, and NIH T32 HL007111) and Mayo Foundation.
Funding Information:
N. Akhiyat was supported by the National Institutes of Health (grant T32 HL007111). The authors acknowledge the Center for Individualized Medicine at Mayo Clinic and the Henry Predolin Leukemia Foundation for providing services. We thank Laura A. Bruins in the Department of Hematology at Mayo Clinic for her help with DNA extraction. The authors thankfully acknowledge statistician support (grant number UL1 TR002377 from the National Center for Advancing Translational Sciences).
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Background: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. The relationship between CHIP and coronary microvascular dysfunction (CMD) is unknown. The current study examines the association between CHIP and CH with CMD and the potential relationships in risk for adverse cardiovascular outcomes. Methods: In this retrospective observational study, targeted next-generation sequencing was performed for 177 participants with no coronary artery disease who presented with chest pain and underwent routine coronary functional angiogram. Patients with somatic mutations in leukemia-Associated driver genes in hematopoietic stem and progenitor cells were examined; CHIP was considered at a variant allele fraction ≥2%; CH was considered at a variant allele fraction ≥1%. CMD was defined as coronary flow reserve to intracoronary adenosine of ≤2. Major adverse cardiovascular events considered were myocardial infarction, coronary revascularization, or stroke. Results: A total of 177 participants were examined. Mean follow-up was 12±7 years. A total of 17 patients had CHIP and 28 had CH. Cases with CMD (n=19) were compared with controls with no CMD (n=158). Cases were 56±9 years, were 68% women, and had more CHIP (27%; P=0.028) and CH (42%; P=0.001) than controls. CMD was associated with independent risk for major adverse cardiovascular events (hazard ratio, 3.89 [95% CI, 1.21-12.56]; P=0.023), and 32% of this risk was mediated by CH. The risk mediated by CH was ≈0.5× as large as the direct effect of CMD on major adverse cardiovascular events. Conclusions: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-Third of major adverse cardiovascular events in CMD are mediated by CH.
AB - Background: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. The relationship between CHIP and coronary microvascular dysfunction (CMD) is unknown. The current study examines the association between CHIP and CH with CMD and the potential relationships in risk for adverse cardiovascular outcomes. Methods: In this retrospective observational study, targeted next-generation sequencing was performed for 177 participants with no coronary artery disease who presented with chest pain and underwent routine coronary functional angiogram. Patients with somatic mutations in leukemia-Associated driver genes in hematopoietic stem and progenitor cells were examined; CHIP was considered at a variant allele fraction ≥2%; CH was considered at a variant allele fraction ≥1%. CMD was defined as coronary flow reserve to intracoronary adenosine of ≤2. Major adverse cardiovascular events considered were myocardial infarction, coronary revascularization, or stroke. Results: A total of 177 participants were examined. Mean follow-up was 12±7 years. A total of 17 patients had CHIP and 28 had CH. Cases with CMD (n=19) were compared with controls with no CMD (n=158). Cases were 56±9 years, were 68% women, and had more CHIP (27%; P=0.028) and CH (42%; P=0.001) than controls. CMD was associated with independent risk for major adverse cardiovascular events (hazard ratio, 3.89 [95% CI, 1.21-12.56]; P=0.023), and 32% of this risk was mediated by CH. The risk mediated by CH was ≈0.5× as large as the direct effect of CMD on major adverse cardiovascular events. Conclusions: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-Third of major adverse cardiovascular events in CMD are mediated by CH.
KW - CHIP clonal hematopoiesis of indeterminate potential
KW - biomarker
KW - coronary artery disease
UR - http://www.scopus.com/inward/record.url?scp=85153981232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153981232&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.122.318928
DO - 10.1161/ATVBAHA.122.318928
M3 - Article
C2 - 36951061
AN - SCOPUS:85153981232
SN - 1079-5642
VL - 43
SP - 774
EP - 783
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 5
ER -